+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Diagnostic tests find out what is happening inside the body, using samples such as blood, urine or tissue. Imaging creates pictures of organs and tissues with X-rays, CT, MRI, ultrasound or PET scans. Medical devices range from simple tools to machin...

Search Bar & Filters

Found 453 Actively Recruiting clinical trials

S

Actively Recruiting

The trial investigates the use of 5-aminolevulinic acid hydrochloride 5-ALA HCl powder for oral solution to help visualize malignant tissue during surgery in adults suspected or confirmed to have malignant high-grade glioma WHO grade 3 or 4. This phase III, multicenter, open-label, single-arm study aims to evaluate both the visualization capability and safety of 5-ALA HCl in this population. The study focuses on determining how well the fluorescent regions correspond to tumor tissue during surgical resection. Participants will receive an oral dose of 5-ALA HCl powder prepared as a solution 3 hours before anesthesia on the day of surgery, dosed at 20 mgkg with a maximum of 1.5 g per participant. Before taking 5-ALA HCl, participants will receive a single 5-mg intravenous infusion of dexamethasone. During surgery, blue-light excitation will be used to visualize fluorescent tumor tissue, and tissue specimens will be collected from fluorescent and nonfluorescent regions for central histopathological assessment. A contrast-enhanced cranial MRI will be conducted 24 to 72 hours after surgery to assess residual tumor. Throughout the study, participants will be protected from light exposure for 48 hours after the study drug. Safety will be monitored through adverse event reporting, physical exams, vital signs, laboratory tests, ECGs, and neurological assessments using the Karnofsky Performance Status and NIH Stroke Scale. The study will measure the proportion of tumor cells in fluorescent tissue specimens as the primary outcome, with secondary outcomes including postoperative MRI findings and histopathological results from various tissue regions. Safety follow-up extends through day 14 after dosing, with all adverse events recorded during this period.

Age: 18Years - 75YearsAll GendersPhase 3
2 locations
E

Actively Recruiting

Researchers are evaluating the usefulness of 68Ga-DOTANOTA-FAPI-04 positron emission tomographycomputed tomography PETCT for diagnosing primary and metastatic lesions across various cancer types. This early phase 1 interventional study aims to assess how well this imaging method detects tumors in patients with suspected, newly diagnosed, or previously treated malignant tumors. Participants receive a single intravenous injection of the 68Ga-DOTANOTA-FAPI-04 drug followed by a PETCT scan within a specified time frame. The study focuses on quantifying tumor uptake using the maximum standard uptake value SUVmax and calculates diagnostic measures such as sensitivity, specificity, positive and negative predictive values, and accuracy. During the study, participants undergo the PETCT scan after injection and provide informed consent. Researchers measure the standardized uptake value within 30 days and evaluate diagnostic efficacy. The study monitors outcomes related to tumor detection, and participation lasts around the time needed for these assessments, with no ongoing treatment or long-term follow-up specified.

Age: 18Years - 90YearsAll GendersEarly Phase 1
1 location
P

Actively Recruiting

Healthy Volunteer

Researchers are investigating a new imaging agent called 68Ga-FAPI-LM3, which targets two receptors SSTR2 and FAP and may help in diagnosing diseases with SSTR2 positive expression. This study evaluates the safety, how the agent spreads in the body, and the radiation dose it delivers in healthy volunteers. Additionally, it compares the usefulness of 68Ga-FAPI-LM3 PETCT scans with the standard 18F-FDG PETCT scans in patients with SSTR2 positive diseases. Participants receive a single intravenous injection of both 18F-FDG and 68Ga-FAPI-LM3, followed by PETCT imaging within a specified time frame. Some participants may also have an additional PETCT scan using 68Ga-FAPI-46 for comparison. The study measures how well 68Ga-FAPI-LM3 detects lesions compared to 18F-FDG, using maximum standard uptake value SUVmax and counting the number of positive lesions. During the study, participants undergo PETCT scans to assess lesion uptake and distribution of the imaging agents. Researchers record the number of lesions detected and evaluate diagnostic accuracy within 30 days. Safety and radiation dosimetry are monitored in healthy volunteers. The total duration of participation varies, with the primary outcome assessed at 30 days and secondary outcomes at 2 days after imaging.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Healthy Volunteer

Researchers are studying a new imaging agent called 68Ga-PSFA, which targets two receptors, PSMA and FAP, to improve the diagnosis of diseases that express these markers. This early phase 1 trial aims to evaluate the safety, distribution in the body, and diagnostic potential of this PET radiotracer for detecting lesions in patients with PSMA or FAP positive diseases. Participants will receive a single intravenous injection of 68Ga-PSFA. This administration is designed to allow imaging of disease sites expressing the PSMA or FAP markers. No placebo or comparison group is involved, and the study focuses on one treatment arm where all patients receive the investigational imaging agent. During the study, participants will be monitored for diagnostic effectiveness within 15 days after injection. Researchers will assess how well the agent detects lesions and track any side effects or safety concerns. The trial is open to adults aged 18 and older who meet certain disease criteria and consent to participate, with no maximum age limit specified.

Age: 18Years +All GendersEarly Phase 1
1 location
U

Actively Recruiting

This research aims to evaluate the use of a specialized imaging technique called 68Ga-labeled targeted covalent radiopharmaceutical TCR fibroblast activation protein inhibitor FAPI PETCT to guide surgery for medullary thyroid carcinoma MTC. Surgery is currently the only curative option for MTC, but existing imaging methods and calcitonin tests are not sufficient to fully map the disease. This study focuses on whether 68Ga-TCR-FAPI PETCT can better identify the extent of MTC and improve surgical planning. Participants are divided into three groups those newly diagnosed with MTC, those with recurrent or persistent MTC after prior treatment, and those with distant or unresectable lesions but still recommended for surgery. Surgery will be performed based on the lesion range revealed by the 68Ga-TCR-FAPI PETCT scan, aiming to remove all identified lesions when possible. The surgical principles follow current standards, including lymph node dissection when needed. During the study, researchers will measure calcitonin levels one month after surgery as the primary outcome. Secondary outcomes include two-year event-free survival, how often surgical plans change based on imaging results, and the accuracy of 68Ga-TCR-FAPI PETCT in detecting MTC lesions. Participants will undergo PETCT scans, surgery guided by imaging findings, and follow-up assessments to monitor outcomes and safety up to two years after surgery.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location
H

Actively Recruiting

Researchers are evaluating the use of high-resolution 7 Tesla MRI imaging of the spine to better distinguish bone spurs from disc material and to more clearly show compressed nerves in the neuroforamen compared to standard 3 Tesla MRI. This study aims to provide surgeons with detailed anatomical images before surgery, potentially reducing the need for CT scans when bone anatomy is crucial. Participants undergo a 7 Tesla MRI scan of the spine, which is a diagnostic imaging procedure. The study compares the 7 Tesla MRIs ability to differentiate compressed nerves with that of the 3 Tesla MRI over a two-year period. This observational study does not involve treatment but focuses on imaging evaluation. During the study, participants will have MRI scans and may provide informed consent for participation. Researchers will assess imaging details to measure how well the 7 Tesla MRI depicts nerve compression compared to standard imaging. The primary outcome is the differentiation of compressed nerves in the neuroforamen over two years. Participants involvement length and visit frequency depend on the imaging schedule and clinical needs.

Age: 18Years +All Genders
1 location
H

Actively Recruiting

Researchers are evaluating the use of high-resolution 7 Tesla MRI to examine the cervical spine with a focus on differentiating nerve roots and surrounding tissues within the neural foramina. This imaging also allows detailed assessment of the vertebral arterys anatomy and its relationship to nearby neural structures. The study aims to establish standard measurements of nerve roots, ganglia, and neuroforamen diameters as reference values. Participants will undergo 7 Tesla MRI scans to capture detailed images of their cervical spine. The study includes individuals over 18 years old who have chronic back pain lasting more than 2 months without recent trauma or prior MRI for clinical reasons, as well as asymptomatic participants to depict normal microanatomy. No treatments are administered, as this is an observational diagnostic imaging study. During the study, participants will be assessed through the MRI scans to measure nerve and ganglia diameters in millimeters and to evaluate the relationship between the vertebral artery and neural structures by checking for the presence of fat tissue between them. These measures will be recorded and analyzed over approximately one year. The study is sponsored by Balgrist University Hospital and will continue until September 2027.

Age: 18Years +All Genders
1 location
P

Actively Recruiting

Healthy Volunteer

Researchers are studying the stimulator of interferon gene STING protein, which plays an important role in the immune systems ability to detect tumors. This trial focuses on evaluating a new imaging agent called 68GaGa-Sa-DABI-4, designed to noninvasively detect STING expression in the tumor environment using positron emission tomography PET. The study aims to assess the safety, distribution in the body, and potential usefulness of this imaging agent for cancer patients. Participants will receive one intravenous injection of the investigational drug 68GaGa-Sa-DABI-4 during the study. This single administration is followed by PET imaging to monitor how the agent interacts with the tumor. The study is conducted in an early phase 1 design, focusing on initial safety and diagnostic capabilities. During the trial, participants will undergo PET scans to evaluate the diagnostic effectiveness of the imaging agent within 15 days after injection. Researchers will monitor safety and how the drug distributes throughout the body. The study includes patients suspected of having or newly diagnosed with malignant diseases. Participation involves a single dosing and imaging session, with safety and diagnostic data collected during this period.

Age: 18Years +All GendersEarly Phase 1
1 location
R

Actively Recruiting

Researchers are collecting real-world data to assess how well Teleflexs vascular access devices perform and how safe they are when used as intended. These devices include various types such as central venous access devices, midline catheters, peripheral catheters, hemodialysis catheters, and arterial catheters with navigation and tip confirmation features. Some of these devices also have properties to reduce infections and blood clots. The study observes patients who need a vascular access device for therapy or diagnosis. It includes a variety of devices and accessories used for their placement and maintenance. The registry tracks the use and performance of these devices without assigning specific treatments, focusing instead on collecting data from routine clinical use. Participants will be monitored for device-related outcomes including the success of device use without removal due to adverse events within seven days after device removal. The study also evaluates how accurately catheter tip locations are verified immediately after removal. Data collection includes monitoring any device-related adverse events during this period. The trial will continue until December 2034, providing extended observation of device performance and safety.

All AgesAll Genders
3 locations
F

Actively Recruiting

Researchers are evaluating the CIPHER System in patients undergoing brain tumor removal surgery for newly diagnosed supratentorial glioma. This First-in-Human clinical investigation aims to assess the safety and basic performance of a novel, highly flexible, electrode-dense cortical probe designed for neurophysiological mapping and stimulation during brain tumor resection. The study focuses on how well the device functions and its handling characteristics during short-term use in surgery. Participants will have the CIPHER Probe placed on the surface of the brain during standard tumor removal surgery. Two groups are studied one where only neural activity is recorded and another where both recording and electrical stimulation are performed using the probe. No stimulation is delivered in the recording-only group. The device is tested on the main tumor area and the surrounding tissue margin just before tumor removal. During the study, participants will be monitored through hospital visits during their recovery period, including follow-ups at two and six weeks after surgery. Researchers will collect data on any device or procedure-related adverse events, spontaneous neural activity, signal quality, and device deficiencies. The total study period includes enrollment through the six-week postoperative follow-up to evaluate safety and device performance.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
1 location

1-10 of 453

1

Frequently Asked Questions